DUBLIN, Aug. 28, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/rktnl9/investigation) has announced the addition of the "Investigation Report on China's Insulin Aspart Market, 2010-2019" report to their offering.

Developed by Novo Nordisk, insulin aspart (under the trade name of Novolog) is an important drug for the treatment of diabetes. Compared with human insulin, insulin aspart, as a fast- acting insulin analog, starts working fast and reports higher peak of glucose- lowering action and lower risk of hypoglycemia. Ever since insulin aspart for injection was approved to enter China in 2012, it has been in the market for over a decade. Although the market is currently dominated by product of Novo Nordisk, some local enterprises are trying to make generic drugs. China Food and Drug Administration (CFDA) announced on its website on Jun.3, 2014 that Hisun's application to produce the APIs of insulin aspart and insulin aspart for injection through recombinant DNA technology has been accepted.

Insulin aspart developed fast after entering China. Its sales value reached CNY 336 million in 2013 and CNY 380 million in 2014 with a year-on-year increase of 13.10% while its sales volume reached 4.42 million in 2013 and 5.01 million in 2014, increasing 13.35% year on year. With economic development and lifestyle changes, the incidence of diabetes in China will keep going up, which fosters the huge demand for insulin aspart. Currently, the market is dominated by Novo Nordisk (Denmark) and Novo Nordisk (China), the former enjoying a larger market share of 100% with sales value reaching nearly CNY 380 million in 2014. As some local enterprises are trying to make generic drugs of insulin aspart, the monopoly of Novo Nordisk is expected to be broken by local products in the next few years.

Key Topics Covered:

1 Related Concepts of Insulin Aspart

2 Market Profile of Insulin Aspart in China

3 Survey on Insulin Aspart Sales in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of Insulin Aspart in China, 2010-2014

5 Survey on Dosage Forms of Insulin Aspart in China, 2010-2014

6 Reference Price of Insulin Aspart in Chinese Hospitals in 2014

7 Major Manufacturers of Insulin Aspart in Chinese Market, 2010-2014

8 Market Outlook of Insulin Aspart in China, 2015-2019

Companies Mentioned

- Novo Nordisk

For more information visit http://www.researchandmarkets.com/research/rktnl9/investigation

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets